# US 2003/0069183 A1 · Lyophilized HGF preparations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069183 A1
- Document ID: US20030069183A1
- Status: Published application
- Kind: A1
- Application number: 10/171,791
- Filed: 2002-06-17
- Published: 2003-04-10
- Earliest claimed: 1995-07-11
- Assignees: Snow Brand Milk Products Co., Ltd.
- Inventors: Katsumi Tanaka; Kanji Higashio; Eitaro Kumazawa
- Web page: https://patentgrep.com/patent/US20030069183A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a lyophilized HGF preparation prepared by lyophilizing an aqueous solution containing HGF, and a lyophilized HGF preparation containing a stabilizer, sodium chloride, a buffer, and/or a surface active agent. According to the invention, HGF can be stabilized, and it can be stored for a long period.

## Claims

### Claim 1

A lyophilized HGF preparation.

### Claim 2 (depends on 1)

The lyophilized HGF preparation of claim 1, wherein the preparation contains a stabilizer.

### Claim 3 (depends on 2)

The lyophilized HGF preparation of claim 2, wherein the stabilizer is glycine, alanine, sorbitol, mannitol, or dextran sulfate.

### Claim 4 (depends on 1)

The lyophilized HGF preparation of claim 1, wherein the preparation contains a buffer.

### Claim 5 (depends on 4)

The lyophilized HGF preparation of claim 4, wherein the buffer is a citrate buffer.

### Claim 6

A lyophilized HGF preparation which contains a stabilizer, sodium chloride, a buffer, and a surface active agent.

### Claim 7 (depends on 2)

The lyophilized HGF preparation of claim 2, wherein the preparation contains glycine or alanine as a stabilizer.

### Claim 8 (depends on 7)

The stabilized lyophilized HGF preparation according to claim 7, wherein said preparation contains a buffer.

### Claim 9 (depends on 8)

The stabilized lyophilized HGF preparation according to claim 8, wherein said buffer is a citrate buffer.

### Claim 10

A method of producing a stabilized lyophilized hepatocyte growth factor (HGF) preparation, which comprises lyophilizing an aqueous HGF solution containing an amino acid, polysaccharides or sugar alcohols as a stabilizer.

### Claim 11 (depends on 10)

The method of producing a stabilized lyophilized HGF preparation according to claim 10, wherein the stabilizer is selected from the group consisting of glycine and alanine.
